May Health
May Health (formerly AblaCare) is a clinical-stage medical device company committed to developing treatment options for women living with PCOS. The company is currently investigating its Ovarian Rebalancing™ treatment in clinical studies; Ovarian Rebalancing is a novel approach to PCOS-related fertility that has the potential to be a safe, straightforward option for activating natural ovulation. May Health is led by a team of serial medtech and women’s health entrepreneurs and executives with extensive experience in product development, validation, and launch. The company has raised €10M in a Series A led by Sofinnova Partners and was founded in 2017 by the firm’s medtech acceleration team, Sofinnova MD Start. May Health is headquartered in Paris, France.
Sector
Medical Devices
Strategies
MD Start & Capital
Status
Live
Website
www.mayhealth.com
Antoine Papiernik
Chairman & Managing Partner, Sofinnova Partners
Anne Osdoit
Partner, Sofinnova Partners - MD Start Strategy
Related News
May Health appoints seasoned medtech executive, Colby Holtshouse, as President and CEO
May Health raises $25 million in Series B funding to advance development for Ovarian Rebalancing therapy
May Health announces data from feasibility studies of its novel Ovarian Rebalancing™ treatment and receives approval from FDA for pivotal trial
May Health completes treatment of five participants in U.S. feasibility study of its Ovarian Rebalancing treatment for PCOS-related infertility
May Health solidifies veteran executive team with appointment of women’s health care leader Anne Morrissey as CEO
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.